Stockreport

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

BioNTech SE - American Depositary Shares  (BNTX) 
PDF Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targetin [Read more]